The United States has approved its first influenza vaccine utilizing mRNA technology, a development that could accelerate updates to seasonal flu shots and bolster preparedness for future pandemics. Moderna's mFLUSIVA received Food and Drug Administration (FDA) approval on August 5, 2026, exactly one year after the Department of Health and Human Services had canceled significant mRNA vaccine projects.

This approval comes despite an earlier decision by Health Secretary Robert F. Kennedy Jr. to cease investment in mRNA vaccine technology, based on claims that these vaccines did not effectively protect against upper respiratory infections. These claims were contradicted by existing data, including Moderna's Phase 3 trial results. The FDA's reversal on reviewing Moderna's application and subsequent approval highlight a significant shift, particularly as the nine experts appointed to review the vaccine unanimously voted in favor of its benefits outweighing its risks, even under the current administration.

Seasonal flu remains a considerable public health concern. The 2024-25 season resulted in 51 million illnesses, 710,000 hospitalizations, and 45,000 deaths, surpassing the number of American fatalities from car crashes in the same period. The health impacts extend beyond acute illness, with a substantially increased risk of heart attack in the week following a confirmed flu infection.

The Limits of Egg-Based Vaccines

For decades, flu vaccines have relied on a laborious process of growing viruses in fertilized chicken eggs, a method dating back to the 1940s. This agricultural approach involves a six-month cycle from strain selection to vaccine production. This lengthy process means that vaccine strains are chosen in February for use in the following November, creating a significant challenge as influenza viruses, particularly the H3N2 strain, drift and evolve.

Furthermore, the adaptation of the virus to grow in eggs can alter the surface proteins that vaccines target, leading to mismatches. Between the 2011 and 2020 flu seasons, these egg-adaptive mutations contributed to vaccine ineffectiveness. While traditional flu shots have prevented thousands of deaths annually, their efficacy has typically ranged between 20 and 60 percent, depending on the match between the selected strains and circulating viruses.

mRNA Technology Offers a Faster Alternative

mRNA vaccines bypass the egg-based production entirely. Instead, they provide genetic instructions that enable a person's own cells to produce the flu's surface protein, prompting an immune response. This approach allows for significantly faster vaccine updates, reducing the timeline from strain selection to finished product from six months to two or three months. This agility means that vaccines could be reformulated closer to the flu season, potentially offering protection against newly emerging strains within the same season.

The mRNA platform's potential extends beyond influenza. Advances have been seen in cancer treatments, with personalized mRNA therapies showing promise in reducing recurrence and death rates for melanoma and pancreatic cancer. mRNA is also being explored as a delivery mechanism for gene-editing therapies. Despite these advancements, the United States risks falling behind, with some mRNA vaccines already licensed in Europe while awaiting resubmission in the US, and critical funding for vaccine development, such as for an H5 bird flu vaccine, being cut.

Challenges to Access and Uptake

While mFLUSIVA demonstrated a significant improvement in efficacy over standard flu shots in clinical trials, its widespread adoption faces hurdles. Approximately two-thirds of recipients experienced injection-site pain, a side effect that could deter some individuals, particularly in a country where a quarter of adults cite side effects as a reason for not getting vaccinated.

Moreover, the frozen status of the CDC's vaccine advisory committee due to a federal court order means there is no official clinical recommendation for mFLUSIVA, impacting insurance coverage requirements. The restoration of canceled government contracts also remains uncertain, leaving questions about the future investment in and accessibility of this new vaccine technology. The reversal of the initial decision to halt mRNA investment was met with confusion, underscoring a need for clearer communication and consistent policy in public health initiatives.